Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?

Author： Pen Claude   Lilliu Hervé  

Publisher： Springer Publishing Company

ISSN： 0928-1231

Source： Pharmacy World and Science, Vol.27, Iss.2, 2005-04, pp. : 83-91

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GPIIb-IIIa antagonists: upstream vs deferred use in acute coronary syndromes

By  

Inpharma, Vol. 1, Iss. 1576, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

GPIIb-IIIa antagonists cost effective in acute coronary syndromes

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Glycoprotein IIb/IIIa Receptor Therapy in Percutaneous Coronary Intervention and Non-ST-Segment Elevation Acute Coronary Syndromes: Estimating the Economic Implications

By Hillegass W.B.  

PharmacoEconomics, Vol. 19, Iss. 1, 2001-01 ,pp. : 41-55

Adis International

Access to resources Recommend Favorite

Update on GPIIb/IIIa antagonists

By Hanson Julien   de Leval Xavier   Kolh Philippe   Supuran Claudiu   Pirotte Bernard   Dogné Jean-Michel  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 8, 2003-08 ,pp. : 1173-1188

Informa Healthcare

Access to resources Recommend Favorite

GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention

By  

Current Pharmaceutical Design, Vol. 10, Iss. 4, 2004-02 ,pp. : 387-398

Bentham Science Publishers

Access to resources Recommend Favorite